<DOC>
	<DOCNO>NCT00493116</DOCNO>
	<brief_summary>This study find Interferon-beta ( IFN-beta ) recover effectiveness washout period patient Multiple Sclerosis previously develop neutralize antibody Interferon-Beta</brief_summary>
	<brief_title>Is IFN-beta Treatment MS Useful After Washout Period Patients With Neutralizing Antibodies Interferon Beta</brief_title>
	<detailed_description>This explorative multi-centre , open label , non-comparative trial investigate whether possible recover IFN-beta efficacy breakthrough relapsing-remitting multiple sclerosis patient high titre neutralize IFN-beta antibody . Prior enrollment , treat MS subject must interferon-beta-1a interferon-beta-1b minimum 12 month reduce bioavailability define relative expression MxA mRNA/GAPDH . Subjects complete washout period concurrent methylprednisolone 500mg PO daily 3 day every month become Neutralizing Antibody negative . Subjects challenge AVONEX 30mcg IM weekly . Bioavailability measure every three month determine return biological activity . Clinical MRI parameter , safety tolerability compare baseline determine efficacy .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Must receive interferonbeta1a interferonbeta1b minimum 12 consecutive month prior enrollment RelapsingRemitting Multiple Sclerosis accord Poser McDonald criterion EDSS score 6 less NAB titre &gt; equal 20 via CPE assay &gt; equal 100 via MxA Protein assay measure least 24 hour last interferonbeta injection two consecutive test least 3 month apart Reduced bioavailability ( relative expression MxA mRNA/GAPDH History severe allergic anaphylactic reaction human albumin , interferon , Methylprednisolone component study drug Clinically significant systemic illness History poorly control hypertension , diabetes , osteoporosis History uncontrolled seizure within 3 month enrollment History Depression suicidal ideation within 3 month enrollment Serious local infection ( abscess cellulitis ) systemic infection within 8 week study abnormal screen blood test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>recovery efficacy</keyword>
	<keyword>MxA protein</keyword>
	<keyword>neutralize antibody</keyword>
	<keyword>Multiple sclerosis</keyword>
</DOC>